Alector

company

About

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.

  • 101 - 250

Details

Last Funding Type
Series E
Last Funding Money Raised
$133M
Industries
Biotechnology,Genetics,Health Care,Therapeutics
Founded date
Jan 1, 2013
Number Of Employee
101 - 250
Operating Status
Active

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$133M
Alector has raised a total of $133M in funding over 2 rounds. Their latest funding was raised on Jul 25, 2018 from a Series E round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 25, 2018 Series E $133M 1 Detail

Investments

Number of Investments
Number of Lead Investments
2
0
Alector has made 2 investments. Their most recent investment was on Jun 21, 2022, when Neol raised $5.20M.
Date Company Name
Round Money Raised Industry Lead Investor
Jun 21, 2022 Neol
Seed $5.20M Blockchain
Dec 9, 2021 Block Earner
Seed $4.50M Blockchain

Investors

Number of Lead Investors
Number of Investors
1
Alector is funded by 1 investors. Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Lilly Asia Ventures Series E